Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with TILA-TACE for hepatocellular carcinoma with pulmonary metastasis
ChiCTR1800018787Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Time to progression. Started Oct 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1800018787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018787.